These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 18619180)
1. Polycystic kidney disease: will it become treatable? Gross P Pol Arch Med Wewn; 2008 May; 118(5):298-301. PubMed ID: 18619180 [TBL] [Abstract][Full Text] [Related]
2. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Wu M; Wahl PR; Le Hir M; Wackerle-Men Y; Wuthrich RP; Serra AL Kidney Blood Press Res; 2007; 30(4):253-9. PubMed ID: 17596700 [TBL] [Abstract][Full Text] [Related]
6. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171 [TBL] [Abstract][Full Text] [Related]
7. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711 [TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. Lieberthal W; Levine JS Am J Physiol Renal Physiol; 2012 Jul; 303(2):F180-91. PubMed ID: 22496407 [TBL] [Abstract][Full Text] [Related]
9. Osmoregulation in Polycystic Kidney Disease: Relationship with Cystogenesis and Hypertension. Underwood CF; Phillips JK; Hildreth CM Ann Nutr Metab; 2018; 72 Suppl 2():33-38. PubMed ID: 29925070 [TBL] [Abstract][Full Text] [Related]
10. Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study. Soliman AR; Ismail E; Zamil S; Lotfy A Transplant Proc; 2009 Nov; 41(9):3639-41. PubMed ID: 19917358 [TBL] [Abstract][Full Text] [Related]
11. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic advances in the treatment of polycystic kidney disease. Riella C; Czarnecki PG; Steinman TI Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484 [TBL] [Abstract][Full Text] [Related]